ATTONasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing next-generation biologic therapies for immune-mediated diseases with high unmet need. Its pipeline includes ATTO-1310, ATTO-2306 and ATTO-1091, which are designed using the company’s ATTOBODY biologics platform, alongside platform licensing and research collaborations such as the EndPath radioligand agreement.

Kysy yhtiöstä

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage product candidates0 %

ATTO-1310 is the lead candidate and is being evaluated in early clinical development.

Preclinical product candidates0 %

ATTO-2306, ATTO-1091 and other programs are being advanced through preclinical development.

ATTOBODY platform0 %

The proprietary biologics platform supports the design of differentiated therapies for immune-mediated diseases.

Licensing and collaboration services100 %

Attovia licenses platform technology and performs research services, including work for EndPath radioligand products.

Asiakkaat

Attovia’s current commercial counterparties are biotechnology companies and strategic partners seeking access to its ATTOBODY technology, exemplified by EndPath’s exclusive worldwide license for radioligand products and related research services. Potential future customers include patients, physicians, hospitals, specialty pharmacies and public or private payors if Attovia obtains approval for its product candidates. Product adoption would depend on clinical benefit, safety, physician acceptance and reimbursement coverage.

Biotechnology and pharmaceutical partners

License Attovia technology or collaborate on development of biologic and radioligand programs.

Clinical research and development partners

Support preclinical studies, clinical trials, manufacturing and regulatory development activities.

Physicians and healthcare providers

Could prescribe Attovia therapies if candidates demonstrate safety, efficacy and regulatory approval.

Patients with immune-mediated diseases

Potential end users seeking improved treatment options for diseases with unmet medical need.

Third-party payors

Public and private insurers may determine coverage and reimbursement for approved products.

Strategia

Attovia is prioritizing development of ATTO-1310, ATTO-2306 and ATTO-1091 while expanding the ATTOBODY platform. The company plans to use third-party manufacturers, research organizations and potential strategic collaborators to advance programs and support eventual commercialization. Over time, it expects to build sales, marketing, market access and distribution capabilities if candidates receive regulatory approval.

Advance lead pipeline candidatesLyhyt aikaväli

Clinical validation is required to establish efficacy, safety and future product value.

Expand the ATTOBODY platformKeskipitkä aikaväli

Additional platform applications could broaden the pipeline and create partnering opportunities.

Build development and commercialization infrastructureKeskipitkä aikaväli

Internal and external capabilities will be needed for trials, regulatory filings and potential launches.

Maantiede

Attovia is headquartered and organized in the United States, where its corporate, research and regulatory activities are managed. The company’s platform license with EndPath is worldwide, creating potential international exposure through partner-led development and commercialization. No country-level revenue or authoritative geographic revenue breakdown is disclosed in the available report excerpts.

Riskit

Attovia has a limited operating history, no approved products and no product-sales revenue, making its business dependent on successful clinical development and regulatory approval. ATTO-1310 is in early clinical development while ATTO-2306 and ATTO-1091 remain preclinical, so failed trials, safety findings or delays could materially impair the pipeline. The company also relies on external manufacturers, CROs, financing sources and potential collaborators, creating execution, funding and intellectual-property risks.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Limited operating history and product concentration1Capital raising and dilution3Clinical and regulatory failure2Manufacturing and supply execution4Commercial adoption and reimbursement5Partner and license dependency6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Limited operating history and product concentrationVaikutus: KriittinenTodennäköisyys: Korkea

    The company has no approved products and depends heavily on three principal candidates.

    KohdistuuFailure or delay of ATTO-1310ATTO-2306 or ATTO-1091 could impair the business
  2. Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Drug candidates must demonstrate safety, efficacy, purity and potency before approval.

    Kohdistuu: ATTO-1310 is early clinical stage; ATTO-2306 and ATTO-1091 are preclinical.

  3. Capital raising and dilutionVaikutus: KorkeaTodennäköisyys: Korkea

    Clinical development requires substantial funding before product revenue is available.

    Kohdistuu: Equity, debt or strategic financing may be unavailable or impose unfavorable terms.

  4. Manufacturing and supply executionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Clinical and commercial supplies depend on CMOs or future internal capabilities.

    KohdistuuManufacturing delaysQuality failures or capacity constraints could delay trials
  5. Commercial adoption and reimbursementVaikutus: KorkeaTodennäköisyys: Matala

    Approved therapies still require physician adoption, payor coverage and patient demand.

    Kohdistuu: Insufficient market access could limit revenue even after regulatory approval.

  6. Partner and license dependencyVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Collaborations may be needed to develop, fund or commercialize programs.

    Kohdistuu: Unfavorable terms could reduce control over intellectual property or future revenues.

Kysy Clarifolta: Attovia Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Collaboration revenue recognition

EndPath revenue is recognized for research and development services rather than product sales.

Vaikutus: Revenue timing depends on performance obligations and contract consideration.

Variable consideration and customer deposits

The EndPath Agreement includes consideration that may not be recognized until applicable conditions are met.

Vaikutus: A customer deposit liability can defer revenue recognition into future periods.

Milestone payments

Development milestones are accrued only when achievement becomes probable.

Vaikutus: Changes in probability can shift research and development expense between periods.

Accrued research and development costs

CRO, CMO, clinical-site and other development work may be billed after services are performed.

Vaikutus: Management estimates affect operating expenses and accrued liabilities.

Stock-based compensation and common-stock valuation

Valuation assumptions affect awards and historical common-stock fair values.

Vaikutus: Changes in estimates can materially affect operating expenses and equity.

Royalty accounting

Royalties are recognized when licensed products are sold and royalties become payable.

Vaikutus: Future product commercialization would create cost-of-sales obligations.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Actinium Pharmaceuticals, Inc.

ATNM · Pharmaceutical Preparations

Atossa Therapeutics, Inc

ATOS · Pharmaceutical Preparations

Atea Pharmaceuticals, Inc.

AVIR · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Päivitetty: 24.9.2026